ICU常规多重耐药菌筛查与ICU获得性血流感染初始抗生素适宜性的关联
本研究为EUROBACT-2前瞻性国际队列研究的亚分析,纳入304个ICU的1800例ICU获得性血流感染成人患者,比较收治ICU是否实施常规MDRO筛查策略与发病24小时内适宜经验性初始抗生素治疗的关系。结果显示筛查组适宜初始治疗率51.8%高于非筛查组43.1%(p<0.001),校正后OR 1.47(95%CI 1.09-1.99;p 0.012),支持常规筛查改善经验性抗生素决策。
要点
- 收治于实施常规MDRO筛查ICU的患者更可能获得适宜初始抗生素治疗。
- 校正混杂后筛查策略与适宜初始治疗独立相关(aOR 1.47,95%CI 1.09-1.99)。
- 该关联在腹腔或呼吸道来源、单微生物革兰阴性BSI中更强。
核心结论
- 入住实施常规MDRO筛查策略的ICU与ICU获得性BSI患者发病24小时内获得更适宜的初始经验性抗生素治疗相关。
- 结果支持常规筛查在改善ICU获得性BSI经验性抗生素决策中的作用。
研究设计与样本
- EUROBACT-2前瞻性国际队列研究的亚分析,纳入304个ICU的1800例ICU获得性血流感染成人患者。
- 暴露为收治ICU的MDRO筛查政策,分为入ICU时普遍筛查±每周筛查与不筛查。
- 主要结局为BSI发病24小时内给予的、与药敏一致的适宜经验性初始抗生素治疗,采用混合效应逻辑回归评估关联。
主要发现
- MDRO筛查ICU患者适宜初始抗生素治疗率为51.8%,非筛查ICU为43.1%(p<0.001)。
- 校正人口学、临床严重程度、聚类效应及ICU层面因素后,筛查策略的保护效应仍显著(校正OR 1.47,95%CI 1.09-1.99;p 0.012)。
- 该关联在腹腔或呼吸道来源BSI、单微生物革兰阴性BSI、抗菌药物耐药率较低的ICU、COVID前时期及同时实施入ICU与每周筛查的ICU中最强。
临床怎么用
- 对ICU获得性血流感染的经验性用药决策,可将收治ICU是否实施常规MDRO筛查作为当地耐药流行病学背景的参考信息。
- 在腹腔或呼吸道来源、疑及单微生物革兰阴性菌BSI时,常规MDRO筛查信息可能更有助于初始抗生素选择。
局限性
- 本研究为队列研究亚分析,筛查策略为非随机暴露,不能排除残余混杂。
- 原文未报告筛查依从性、具体筛查方法及经验性用药方案细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether hospitalisation in an intensive care unit (ICU) with a routine multidrug-resistant organism (MDRO) screening policy increases appropriate initial antibiotic therapy (IAT) for treatment of patients with ICU-acquired bloodstream infections (BSIs). METHODS: A subanalysis of the EUROBACT-2 prospective international cohort study, including adult patients with ICU-acquired BSI. Exposure was the admitting ICU's MDRO screening policy, classified as universal on-admission ± weekly screening versus no screening. Primary outcome was appropriate, empiric IAT given within 24 hours of BSI onset, which was concordant with antimicrobial susceptibilities. Associations were evaluated using mixed-effects logistic regression models. Subgroup analyses by BSI source, causative pathogen, local epidemiology and time period were completed. RESULTS: Overall, 1800 patients with ICU-acquired BSIs from 304 ICUs were included. Patients were significantly more likely to receive appropriate IAT in the first 24 hours of the BSI onset when hospitalised in MDRO screening versus non screening ICUs (51.8% versus 43.1%; p <0.001). Considering patients' demographics, clinical severity, clustering effects and ICU-level factors, the protective effect of MDRO screening policy remained significant (adjusted OR 1.47, 95% CI 1.09-1.99; p 0.012). This association was strongest in patients with intra-abdominal or respiratory BSI sources, monomicrobial Gram-negative BSIs, ICUs with lower antimicrobial resistance prevalence, in the pre-COVID period and in ICUs performing both on-admission and weekly screening. CONCLUSIONS: More appropriate IAT for ICU-acquired BSIs was given when patients were hospitalised in ICUs practicing routine MDRO screening. These results support the role of regular screening in improving empiric antibiotic decision making for ICU-acquired BSIs.
引用
- Hassoun-Kheir N, Tabah A, Barbier F, et al. Screening for multidrug resistance carriage and appropriate initial antibiotic treatment of intensive care unit-acquired bloodstream infections. Clin Microbiol Infect. 2026. PMID: 42546924. doi:10.1016/j.cmi.2026.07.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。